Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC)
| 2.99 Data as of May 22 |  -0.08 / -2.61%Today’s Change | 2.91 Today|||52-Week Range 8.18 | -50.66% Year-to-Date |
Latest CYCC News | Press Releases
No recent news for Cyclacel Pharmaceuticals Inc.
Today’s Trading
| Previous close | 3.07 |
| Today’s open | 3.05 |
| Day’s range | 2.91 - 3.13 |
| Volume | 583,707 |
| Average volume (3 months) | 182,929 |
| Market cap | $53.9M |
| Dividend yield | -- |
Data as of 4:00pm ET, 05/22/2013
Growth & Valuation
| Earnings growth (last year) | +25.00% |
| Earnings growth (this year) | +16.67% |
| Earnings growth (next 5 years) | -- |
| Revenue growth (last year) | -90.13% |
| P/E ratio | NM |
| Price/Sales | 728.24 |
| Price/Book | 2.66 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| CBRXColumbia Laboratorie... | 0.00 | 0.00% |
| CMXICytomedix Inc | -0.01 | -1.76% |
| ATNMCactus Ventures Inc | +0.07 | +1.83% |
| VTUSVentrus Biosciences ... | +0.01 | +0.38% |
Data as of 4:00pm ET, 05/22/2013
Financials
| Last reporting date | -- |
| EPS forecast (this quarter) | -- |
| Annual revenue (last year) | $69.0K |
| Annual profit (last year) | -$13.2M |
| Net profit margin | -19,936.23% |
Profile
Sector Health Technology |
Industry Biotechnology |
President, Chief Executive Officer & Director Spiro Rombotis, MBA |
COO, CFO, Secretary, Director & Executive VP Paul McBarron |
Corporate headquarters Berkeley Heights, New Jersey |
Forecasts
